TetraQ assists clients to assess the efficacy of potential new pharmaceuticals in development for the treatment of human disease, with a focus on in vivo models. In vitro efficacy assays are also undertaken depending on the client's requirements.
Several in vivo models can be conducted in a "screening" format to minimise costs and provide proof-of-concept data for a panel of compounds. Candidate confirmation studies typically involve a more thorough examination of efficacy and rodent disease models are chosen based on their acceptance in the relevant field.
TetraQ offers a range of in vivo disease models and develops and validates new disease models as part of its research activities. To tap into these capabilities, please Contact Us. The full details on all available models are documented in Fact Sheets.
Pain models include:
- Acute and Persistent Nociceptive Pain
- Chronic Inflammatory Pain
- Neuropathic Pain
- Mechanical Nerve Injury
- Diabetic neuropathy: Type 1 and Type 2
- Chemotherapy-induced neuropathy
- Anti-retroviral drug (ddC)-induced neuropathy
- Post-herpetic Neuralgia
- Bone Cancer Pain
TetraQ has established a network of early phase clinical research units and regulatory consultants to transition new pain medicines from preclinical to clinical testing.
CNS and other disease models include:
- Multiple Sclerosis
- Respiratory Depression